Skip to main content
Premium Trial:

Request an Annual Quote

Variantyx Raises $41.5M in Second Series C Funding Round

NEW YORK – Genomics analysis firm Variantyx said on Monday that it has raised $41.5 million in a Series C-2 funding round.

New Era Capital Partners led the round, joined by Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech.

In a statement, the company said it will use the funding to grow and to launch its whole-genome analysis technology, with a focus on precision oncology.

Framingham, Massachusetts-based Variantyx has expanded into oncology and prenatal testing after launching in 2014 as a clinical decision support engine. The company, which raised at least $26 million in Series C financing last year, has licensed genomic analysis technology from Israel's Tel Aviv University.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.